Dr Scott Tagawa speaks to ecancer about data he presented at ESMO 2025 on [177Lu]Lu-PSMA-617 combined with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitor (ARPI) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Dr Tagawa reports that the PSMAddition trial demonstrated benefits with acceptable safety in this patient population with a primary endpoint of the study as radiographic progression-free survival. He comments that the study authors hope to have more details in terms of patient reported outcomes and other correlative analyses coming in the future.